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Abstract
Objective: To evaluate recently reported findings on necrotizing enterocolitis, paying particular attention to
pathogenesis, management and preventative strategies.
Data sources: The articles covered in this report consist of randomized and quasi-randomized trials, case
control studies, meta-analyses and reviews published recently. Certain other articles were also included because
of their utmost importance to the subject.
Results: Necrotizing enterocolitis remains a major cause of morbidity and mortality in preterm infants. Those
who are born with intra-uterine-growth retardation are at a several-fold increased risk. Possible pathophysiologic
processes beginning in utero and continuing after birth are discussed in this review. Other factors involved in the
process are related to the role of arginine and the production of intestinal nitric oxide and the action of epidermal
growth factor in the regulation of cell regeneration. Perforated necrotizing enterocolitis is a complex surgical
problem; definitive evidence-based guidelines for the best approach are yet to be determined. After surgery,
although residual small bowel length and the presence of the ileo-cecal valve remain important predictors of duration
of parenteral nutrition in infants, other factors, such as the early use of breast milk or amino acid-based formula,
may also play a role in intestinal re-adaptation. Prevention strategies have centered on feeding practices and
emerging experiments such as amino acid supplementation, are also discussed.
Conclusion: Significant results in terms of mortality and morbidity will be achieved through better understanding
of necrotizing enterocolitis pathogenesis and clinical and surgical management in addition to the employment of
preventative strategies.
J Pediatr (Rio J). 2005;81(1 Suppl):S16-S22: Necrotizing enterocolitis, prematurity, short bowel syndrome.
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Introduction
Necrotizing enterocolitis (NEC) is a clinicopathological
syndrome characterized by progressive gastrointestinal
and systemic signs and symptoms of varying intensity
resulting from coagulation necrosis of the gastrointestinal
tract, generally located in the terminal ileum, ascending
colon and the proximal transverse colon.1 It affects premature
babies with greater frequency, in particular those who are
born with weights of less than 1,500 g, and just 5 to 10%
of classic cases of the disease affect full term babies.2-4 It
is estimated that the disease affects between 5 and 15% of
premature infants and around 7% of fullterm neonates
admitted to neonatal intensive care units.5 Recent
observations have revealed an increase in the incidence of
NEC. In the USA, the estimate is a figure of 6,000 cases
annually.6,7
In general the clinical manifestations occur during the
first week of life,2,3,8 although some centers report later
onset.9 This pattern is typically observed among premature
infants when they are in a convalescent phase, recovering
from the base disease. In full term newborns, however,
manifestations generally occur during the first days of life.
Symptoms have a wide variation in terms of presentation,
from non-specific cases with mild abdominal distension,
increased gastric residue, lethargy and thermal instability,
to the most obvious cases with pronounced abdominal
distension, enterorrhagia, signs of peritonitis, sepsis, septic
shock and multiple organ failure.10-12 Staging of NEC based
on clinical and radiological findings has proven useful in
guiding treatment and for prognostic assessments.10,13 In
daily practice it is only possible to define the final stage of
severity of the disease from the second day of manifestation
onwards. In cases where only mild systemic and abdominal
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findings are observed over the first 48 hours of the course
of the disease it is unlikely that there will be a more serious
outcome.10 However, it should be remembered that in
practice the velocity with which clinical decline takes place
can not be predicted.
Despite the achievements observed in perinatal care
over the last decade, the prognosis of newborns with NEC
has not improved. In fact, over recent years a tendency has
been observed for the number of deaths from this condition
to increase.14 The mortality rate is between 18 and 45%,
depending upon the degree of prematurity and the severity
of infection. Furthermore, survivors present a great risk of
developing stenosis of the affected segment and short
bowel syndrome.9,13-17
While the exact cause is still considered an enigma, it is
accepted that NEC results from an initial insult to the
intestinal mucosa, resulting from the action of a variety of
factors on an immature gastrointestinal system, followed by
a series of inflammatory reactions in cascade, proliferation
and bacterial invasion of the intestinal mucosa culminating
in coagulation necrosis of the affected areas. This article
aims to review the most recent aspects involved in the
etiopathogenesis of NEC, exploring factors involved in
better management and prevention of the condition.
Etiopathogenesis
The role of intrauterine growth impairment,
gastrointestinal immaturity and perinatal asphyxia
It is still customary to state that babies born small for
gestational age (SGA) exhibit accelerated organ maturation
due to intrauterine stress and are therefore less prone to
express the problems that result from prematurity when
compared with premature newborns born at weights
appropriate for gestational age. This statement, however,
has been contested by a number of different recent
observations which indicate that SGA preterms are a high
risk group for developing NEC, when compared with those
born at adequate weights. Thus,  Zaw et al.7 analyzing the
appearance of NEC among premature infants with gestational
ages of less than 34 weeks, showed that intrauterine growth
impairment increased the risk of the occurrence of the
disease when they evaluated patients using neonatal growth
standards (RR 2.47; 95% CI 1.21; 5.07), although they did
not observe the same effect when they used intrauterine
growth curves for classification (RR 1.78; 95% CI 0.93;
3.38). Similarly, Bernstein et al., analyzing the Vermont-
Oxford networks database for premature infants born at
gestational ages between 25 and 30 weeks, found an
increased occurrence of the disease among those that
presented retarded growth (RR 1.27; 95% CI 1.05; 1.53).18
Hallstrom et al.19 studied newborn babies with gestational
ages of less than 33 weeks and observed that growth
impairment was a significant risk factor for developing the
more severe forms of the disease (RR 4.55; 95% CI 1.00;
19.5). More recently Garite et al.20 evaluated around
30,000 premature newborn babies over 5 years and observed
that for the same weight, SGA babies had older gestational
ages and therefore appeared to have better prognosis.
However, when the children were matched for gestational
age, the group with intrauterine growth impairment exhibited
greater risk of death, of developing NEC, of oxygen
dependency at 28 days of age and of presenting retinopathy
of prematurity. It is believed that in situations where there
is growth impairment, intrauterine hypoxia promotes a
redistribution of cardiac output depriving the immature
intestine of adequate oxygenation and thus contributing to
the development of NEC.21 Doppler studies assessing blood
flow showed a reduction in flow velocity through the superior
mesenteric artery and celiac trunk of fetuses who progress
with growth retardation. This alteration remains after birth,
during the first week of life, leading some authors to believe
that the greater postnatal mesenteric vascular resistance is
programmed during intrauterine life.22 In an attempt at
early identification of those newborns who had suffered
form a state of chronic intrauterine asphyxia, and thus
obtain a marker of risk of NEC, Mandel et al. retrospectively
investigated 23 premature infants who had had the disease
confirmed (Bell stage II). The authors observed that
reticulocytosis was a statistically significant variable for the
group with NEC when compared with the controls, suggesting
that an elevated reticulocyte count may allow the definition
of a subset of preterms at greater risk of developing the
disease.23
The role of amino acids
The adequate growth and development of the
gastrointestinal tract and its ability to sustain a series of
digestive and absorbent functions is dependent on an
appropriate supply of a number of different nutrients.
Arginine is an amino acid that can be synthesized by
enterocytes and is a primary source of nitrogen for local
nitric oxide production.24 Nitric oxide is a potent mediator
that induces relaxation in vascular smooth muscle and, in
this manner, regulates the basal tone of the arterioles,
performing an important role in the control of blood flow
to the intestinal mucosa. Studies of experimental models
using ischemia, hypoxia, toxins or platelet activating
factor to induce intestinal damage have shown that
inhibiting nitric oxide synthesis is associated with increased
tissue damage whereas if it is supplied exogenously the
effect is attenuated.25-27 Some studies have demonstrated
lower plasma levels of arginine and glutamine in premature
newborn babies suffering from NEC than in babies without
the disease.28,29 Di Lorenzo et al. showed that a continuous
infusion of arginine attenuated intestinal injury in an
experimental model.30 In a similar manner, Akisu et al.
found that oral supplementation of arginine and carnitine
(an amino acid with antioxidant properties) significantly
reduced intestinal tissue damage in mice subjected to
hypoxia followed by re-oxygenation.31 In a prospective,
randomized and blind study of humans, Amin et al.
analyzed the effect of supplementing with 1.5 mmol/kg
per day of L-arginine premature infants with gestational
ages of less than 32 weeks and birth weights below
1,250 g.32 The authors observed that prophylactic arginine
supplementation reduced the incidence of NEC at all
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stages (7 versus 27%). Although further studies are
needed to explore the true role of supplementation with
amino acids like carnitine and arginine in the genesis of
NEC, the fact that their administration can reduce the
incidence of the disease is an exciting fact awakening
great promise for future preventative actions.
The role of epidermal growth factor
Epidermal growth factor (EGF) belongs to a vast family
of peptides (transforming growth factor-alpha, amphiregulin,
heparin-binding EGF, epiregulin, betacellulinn and
neuroregulin, among others) which provoke a variety of
biological responses in the gastrointestinal tract, the majority
of which involve regulation of cell replication and cell
movement and survival. This family of peptides has an
affinity for a specific receptor, the EGF receptor, which can
be found distributed across the entire gastrointestinal tract
of the fetus and neonate.24 The exact location of these
receptors in the small intestine is in the baso-lateral
compartment of epidermal cells and the apical membrane of
the villous epithelium. The earliest evidence relating EGF
and NEC was found by Sullivan et al. These authors described
the case of a child of 8 months with a case of intestinal
necrosis similar to NEC and for whom continuous EGF
administration over a period of 4 days led to recovery.33
Soon Scott et al. had observed a high rate of urinary
excretion of EGF in newborns with NEC. The authors
speculated that this fact could be the result of greater EGF
absorption by the injured intestine.34 Other studies point to
the association between low levels of EGF in saliva and
serum and NEC,35,36 with some authors raising the hypothesis
that EGF administration could be active in both prevention
and treatment of the disease.36 Wong & Wright summarize
current knowledge on the role of EGF in the growth and
development of the gastrointestinal tract, pointing out that
intra-luminal or parenteral administration could be a powerful
weapon for protection and regeneration of intestinal cells.37
Clinical and surgical management
Surgical approach
Considered the most common surgical emergency during
the neonatal period, the operative approach to NEC still
provokes doubts, whether with respect of the best time to
intervene or the best technique to use because of the
different stages of the disease and the great variability in
weight and gestational age of the patients affected.
In clinical practice, all patients presenting with intestinal
perforation are potential candidates for surgical treatment.
The radiological finding most often associated with perforation
of intestinal loops is the presence of pneumoperitoneum
observed in antero-posterior x-rays of the abdomen or,
preferably in left lateral decubitus with horizontal rays.
However, Kosloske studied prospectively a cohort of 147
children, observing that pneumoperitoneum, as a sign of
intestinal perforation, was present in just 48% of cases,
although specificity was 100%. Other findings considered
diagnostic of perforation were the presence of liquid with a
fecal or bilious appearance or the detection of germs with
Grams staining in material obtained by paracentesis. Relative
indications for surgical intervention were the presence of air
in the portal system, intestinal loops in a fixed position over
serial x-rays of the abdomen, erythema of the abdominal
wall or a palpable mass in the abdomen.38 In daily practice,
however, the decision on the need for intervention and the
most suitable time is, in the majority of cases, individualized,
being based on the evolving analysis of clinical, laboratory
and x-ray findings. Furthermore, it should be borne in mind
that these patients very often are in a critical state, making
the decision more difficult. The decision should, preferably,
be taken in conjunction by the multidisciplinary team of
surgeon, anesthetist and neonatologist.
The two most common procedures are simple peritoneal
drainage and explorative laparotomy with resection of the
affected segment followed by primary anastomosis or
enterostomy. Leaving to one side individual preferences for
laparotomies with resection or simple peritoneal drainage,
a tendency is observed in the relevant literature to indicate
the latter procedure for patients of lower weight or younger
gestational ages and suffering from a greater number of
aggravating factors. Erlich et al., reviewing the surgical
procedures performed on 70 newborn babies with birth
weights of less than 1,000 g who had developed NEC,
observed a survival rate of 63% among children who
underwent peritoneal drainage and 75% among those
subjected to laparotomy. However, the patients who
underwent peritoneal drainage presented a greatly increased
number of complications. Using a regression analysis the
authors concluded that the choice of surgical operation had
not influenced the final outcome.39 Recently, Moss et al.
performed a meta-analysis of studies that had used both
procedures to treat children with NEC. The analysis covered
475 patients and did not reveal statistically significant
differences between laparotomy and peritoneal drainage in
terms of mortality. It did, however, call attention to a
significant selection bias since the average weight of the
children subjected to laparotomy was 1,615 g while that of
the children who underwent drainage was 931 g (p = 0.0004).
The authors therefore concluded that, using uncontrolled
data, there is no evidence for concluding whether laparotomy
or peritoneal drainage is the better surgical approach.40 The
results of that study formed the basis for a multicenter
randomized clinical trial, currently in progress, that unites
13 North-American institutions under the supervision of the
National Institutes of Health.41
Parenteral and enteral nutrition
Short bowel syndrome is one of the most significant
complications secondary to NEC in which there was a need
for extensive intestinal resection. It is known that after
resection the remaining section of the intestine undergoes
a process of adaptation characterized by hyperplasia of the
mucosa, increase in villous extension, deepening of the
crypts and dilation of the intestine.42,43 The use of parenteral
nutrition to meet nutritional requirements is an important
tool to enable intestinal function to be recovered, permitting
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enteral nutrition, sequentially instituted, to gradually
substitute the parenteral modality. Nevertheless, the clinical
course of patients with short bowel syndrome is very often
unpredictable, meaning that parenteral nutrition can be
used for prolonged periods and, in certain situations for
indeterminable periods as a result of the intestine failing to
readapt to full enteral nutrition. This, in turn increases the
risk of complications such as infectious processes,
cholestasis, inadequate bone mineralization and death.
Andorsky et al., aiming to analyze the factors that influence
the duration of and dependence on parenteral nutrition,
retrospectively studied 30 children with short bowel
syndrome, around half of whom had the syndrome as a
result of NEC. The definition of short bowel syndrome was
restricted to neonates who had undergone intestinal resection
and/or intestinal malformation and required at least 90
days parenteral nutrition. Enteral feeding was instituted
with small quantities of maternal breastmilk or amino acid
formula (Neocate, SHS Inc), which were gradually increased
in accordance with patient tolerance. The authors observed
that the presence of an intestinal segment greater than
83 cm (– 67cm) (r = -0.475) and enteral feeding with
maternal milk (r = -0.821) or amino acid formula
(r = - 0.793) were associated with shorter period of
parenteral nutrition use. Furthermore, they noted that the
use of maternal breastmilk was the factor that showed the
greatest correlation with the period of parenteral nutrition.44
In this series there was no relation between maintenance of
the ileocecal valve and the duration of parenteral nutrition,
which some other studies have found to be significant.45,46
Early institution of enteral feeding appears to exercise a
series of benefits on these patients recovery, in particular
when maternal breastmilk was used as a result of the
immunological factors and EGF it contains.24,44 Thus,
Bohnhorst et al. studied the postoperative progress of
children with NEC at Bell stages II and III who had been
subjected to intestinal resection taking into consideration
the differences resulting from the time of reintroduction of
enteral feeding with formulae.47 Group 1, composed of 26
children, were reintroduced to feeding in an average of 4
days (3-14 days) and in group 2, composed of 18 children,
the average time before reintroducing feeding was 10 days
(8-22 days). The early group exhibited a shorter period
before achieving total enteral feeding (10 days versus 19
days, p < 0.001), shorter period of central venous access
(13.5 days versus 26 days, p < 0.1), lower percentage of
catheter-related sepsis (18% versus 29%, p < 0.1) and a
shorter length of hospital stay (63 days versus 69 days,
p < 0.5). More recently, Quirós-Tejeira et al., in an
uncontrolled study, retrospectively analyzed data from 78
children with short bowel syndrome who had required
parenteral nutrition for a period of more than 3 months.48
The authors observed that the best survival rate was
associated with a remaining small intestine segment of
more than 38 cm, an intact ileocecal valve, intestinal
reconstruction after stomas and primary anastomosis. The
use of parenteral nutrition, early onset and persistent
cholestasic jaundice, and also a small intestine remnant
smaller than 15 cm, were associated with increased mortality.
There was a smaller chance of intestinal readaptation if the
extension of remaining small intestine was less than 15 cm,
if the ileocecal valve or colon were resectioned and if
primary anastomosis could not be performed. The survival
rate of the sample analyzed was 73%, with 77% of the
survivors achieved intestinal readaptation.
Preventive measures
Over the years a number of different strategies have
been developed to prevent the appearance of NEC. However,
to date the majority of these measures are based on clinical
observation and some experimental data.
Antenatal corticoid therapy
Since premature birth is the most important risk factor
for developing NEC, the possibility that intestinal
maturation could be induced medicinally with antenatal
corticosteroid has been investigated. In a randomized
multicenter study, Bauer et al. observed a significant
reduction in the incidence of NEC among children whose
mothers had received corticosteroid during the prenatal
period.49 The same result was presented by Halac et al.
in a controlled trial.50 Smith et al. retrospectively analyzed
the progress of children whose mothers had received one
course, multiple courses or no courses of antenatal
corticosteroid. The authors observed that those who had
received one course of medication presented a lower
incidence of NEC.51 Other experiments, however, have
not demonstrated the same results. Kamisuka et al.,
analyzing premature infants born at gestational ages of
less than 35 weeks and with birth weights between 1,250
and 2,500 g, observed an incidence of NEC that was twice
as frequent among the children whose mothers had
received antenatal corticosteroid.52 Similarly, Guthrie et
al., analyzing the databases of 98 North-American neonatal
intensive care units, observed that exposure to antenatal
steroids increased the risk of the appearance of NEC.53
Despite these findings, the use of antenatal steroids is
currently defined as an important measure for reducing
morbidity and mortality resulting from pulmonary
immaturity and prematurity. Due to the great stimulus
towards using antenatal corticosteroid nowadays, over
the next few years more and more premature babies will
be exposed to the medication before birth and it is
possible that the relation between the use of corticosteroid
and incidence of NEC will become clearer.
Early closing of patent ductus arteriosus
It is known that the presence of patent ductus arteriosus
(PDA) promotes the diversion of blood volume to the
pulmonary arteries in the diastolic phase, which leads to
the reduction of splenic perfusion, thus increasing the risk
of NEC.54 In a controlled and randomized trial with
premature infants with birth weights less than or equal to
1,000 g, Cassady et al. observed that early surgical
ligature of the ductus arteriosus reduces the chance of
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NEC developing.55 From the eighties onwards indomethacin
began to be used prophylactically for closing ductus
arteriosus and prevention of intracranial hemorrhage.
The research that followed showed an effective action in
reducing these situations although side effects such as
reduced splenic blood flow put a check on the universal
recommendation for their usage.56 Thus, Grosfeld et al.
reported an increase in the incidence of NEC and intestinal
perforation in children who received indomethacin for
PDA treatment.57 In the same area of research, Pezzati et
al.58 studied the effect of indomethacin and ibuprofen on
blood flow through the superior mesenteric and renal
arteries, in children with PDA. The authors observed that
indomethacin caused a significant reduction of blood flow
through these vessels after 30 minutes. Also of interest
was that even after 120 minutes the flow intensity had not
returned to the base values observed before treatment.
The same situation was not observed with the use of
ibuprofen. On the other hand, in a retrospective study
ODonovan et al.59 observed that the use of indomethacin
for PDA treatment was not associated with an increased
risk for the appearance of NEC. More recently, Cooke et
al., in a review analysis for the Cochrane Library, concluded
that there was no evidence that the use of indomethacin
was associated with an increased risk of NEC.60
Enteral antibiotic therapy and immunoglobulins
Based on the theory that bacterial colonization and
subsequent proliferation on the surface of the damaged
intestinal mucosa contributes to the appearance of NEC,
a number of different studies, with conflicting results,
used antibiotics by enteral route (aminoglycosides in
general) to prevent the condition.61-63 In a prospective,
randomized and double-blind study, Siu et al. evaluated
vancomycin for NEC prophylaxis.64 The authors observed
a reduction in the condition in the treatment group (13%
versus 27%). In a review study for the Cochrane Library,
Bury & Tudehope evaluated five studies that used
antibiotics via enteral route for NEC prophylaxis in low
birth weight premature infants. The collective analysis of
these studies suggests that antibiotic therapy by enteral
route significantly reduces both the incidence and related
deaths of NEC. Overall, they concluded that because of
the pronounced risk of encouraging resistant bacterial
strains, the existing evidence did not justify the
administration of antibiotics by enteral route for NEC
prevention.65
Since premature infants have low levels of
immunoglobulins, particularly secretory IgA, a series of
research projects have been performed to observe the role
of the prophylactic use of oral immunoglobulins in the
prevention of NEC. In a randomized clinical trial, Eibl et al.
evaluated the efficacy of an oral preparation of
immunoglobulins (73% - IgA and 26% - IgG) for preventing
NEC in children who had not received maternal milk.66 The
authors observed a significant reduction in cases of NEC in
the treatment group (0% versus 6.6%). In a similar manner,
Rubaltelli et al. noted a significant reduction in NEC cases
among children fed exclusively on formula after the
administration of an oral immunoglobulin preparation
containing 90% of IgG.67 Nevertheless, Foster & Cole
performed a meta-analysis for the Cochrane Library,
concluding that the currently existing evidence does not yet
support the use of oral immunoglobulin in clinical practice
for NEC prevention.68 Similarly, the use of intravenous
immunoglobulin, despite having evidence in its favor in
terms of reducing nosocomial infections, did not demonstrate
beneficial effects for the prevention of NEC.69
Amino acid supplementation
It is known that the classic histopathological finding in
NEC is coagulation necrosis, which presupposes the previous
action of local or systemic ischemic events. In the knowledge
that such phenomena might be involved in the pathogenesis
of NEC,70,71 the role of the vasodilatory action of nitric oxide
has acquired special importance. The nitric oxide is produced
during the enzymatic conversion of L-arginine into under
the synthase action of nitric oxide. As has been explored
above, supplementation with exogenous arginine appears
to demonstrate elements that are promising for the
prevention of NEC.30-32
Maternal breastmilk
Epidemiological studies and experimental models have
shown that the use of maternal milk for feeding premature
infants reduce the incidence of NEC.72,73 Thus, studies
show that preterm newborns fed exclusively with formula
have a risk from six to 10 times greater of developing the
condition when compared with children who received
human milk.74 It is known that human milk contains a
multitude of factors, such as immunoglobulins,
erythropoietin, interleukin-10, EGF and  acetylhydrolase,
among others, that act to prevent NEC appearing.75 The
presence of platelet activation factor (PAF), for example,
has been implicated in the etiopathogenesis of NEC.76
Elevated concentrations of PAF have been found in newborn
babies with NEC, while levels of the enzyme that provokes
its hydrolysis (acetylhydrolase) were reduced.77 Human
milk, and not bovine milk, is an important source of
enzymes that lead to PAF hydrolysis. Another important
datum is that human milk contains elevated levels of EGF,
which cannot be found in commercial formulae.75
Recently McGuire & Anthony,78 in a systematic review,
analyzed four randomized or semi-randomized studies
that compared the effect of banked human milk compared
with formula on the appearance of  NEC in premature
infants born at weights of less than 2,500 g. The meta-
analysis showed that those children who received human
milk presented a four times smaller risk of developing Bell
stage II NEC. The authors comment that although
pasteurized human milk has a lower protein content than
a babys own mothers milk, the presence of anti-infectious
and immunological factors and EGF offer children protection
in contrast with formulae which only present nutritional
components.
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Pre and probiotics
Probiotics are live microorganisms offered as nutritional
supplements (for example bifidobacterium), which act within
the intestine of the host organism regulating the local
bacterial flora. This being so, they act to improve
gastrointestinal permeability, increasing mucosal resistance
against bacterial penetration. Prebiotics, for example, are
indigestible nutritional ingredients (for example
oligofructose), which selectively stimulate the growth of
benign bacterial species present in the colon, such as
lactobacillus and bifidobacterium. To date, the evidence on
the role of pre and probiotics in the prevention of NEC is
based on reports of experiments with historical controls and
on experimental models. Further studies are necessary
which evaluate the true role of these products in a controlled
manner, but they appear to be a promising weapon in the
management of NEC.73
Conclusions
Although NEC remains one of the major challenges in
neonatology, much knowledge has been accrued explaining
its etiopathogenesis and opening fresh eyes to its
management and prevention. The role of amino acids such
as arginine and carnitine, the importance of EGF, the action
of enzymes that provoke hydrolysis of platelet activation
factor and the role of fetal programming caused by
retarded intrauterine growth, are some of the pillars that
will certainly have an influence, over the short term, on new
approaches to the management of newborn babies suffering
from NEC. Special attention has also been seen in the
surgical approach, where more criteria-based techniques
are being sought which are capable of affording better
results over the long term, particularly with respect of the
management of extremely low weight premature infants
and the short bowel syndrome. Nowadays, the knowledge of
the importance of the role of maternal breastmilk in the
prevention and treatment of NEC is ever more firmly based.
Therefore, the implementation of measures stimulating its
use is a determinant marker of better results.
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